Jeanne Whalen at the Wall Street Journal examines the restructuring of R&D at GlaxoSmithKline, and other big drug companies, over the past decade. GSK "has carved its research group into dozens of such small units" in an effort to "turn a sluggish, bureaucratic R&D staff into a constellation of specialized teams capable of discovering cutting-edge drugs — much in the way biotech companies do,"she writes.